Pimasertib hydrochloride

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NamePimasertib hydrochloride
Drug Alias Namepimasertib匹玛舍替派吗色替MSC-1936369A (free base)MSC-1936369B +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsBrain metastasesSkin MelanomaSolid tumours +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSanthera Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesKazia Therapeutics Ltd
Inactive CompaniesMerck Serono SaEmd Serono IncThe University Of Texas MD Anderson Cancer Center +[6] 
Active IndicationsSolid tumoursBrain Neoplasms
Inactive IndicationsBrain metastasesSkin MelanomaCarcinoma, Non-Small-Cell Lung +[16] 

Other Information

ATC CodeN/A
Related LinksKEGG